Stephen Morales is an accomplished healthcare strategy consultant at Blue FIn Group with a distinguished 25-year career in the life sciences sector. His expertise centers on quantifying and realizing value from innovative treatments, market access programs, and product launch excellence. Stephen Morales has supported large pharma and biotech clients as they create and execute strategic market access programs. With a profound understanding of a variety of regulatory and reimbursement landscape frameworks, he has spearheaded global product launches and developed transformational strategies across multiple therapeutic areas, including cardiovascular disease, diabetes, obesity, neurology, oncology, and advanced therapies in cell and gene. His recent work involves advising corporate, venture capital, and private equity clients on the implications of the Inflation Reduction Act on therapy access and the variety of strategic and tactical steps that companies can take in the coming years. Stephen is sought out for his grasp of the US reimbursement framework in the context of other international health system designs. Stephen's background also spans specialty pharmacy, cell and gene therapy, digital therapeutics, and medical technology sectors, having worked for Merck, Baxter, and Abbott. He collaborates with global supply chain executives, striving to mitigate barriers and enhance patient health outcomes worldwide. Stephen is a graduate of MIT and Duke's Fuqua School of Business.